REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedReviewHuman Subjects

Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.

Huth Alina, Ayoub Ikram, Barateau Lucie, Gerdes Lisa Ann, Severac Dany, Krebs Stefan, Blum Helmut, Tumani Hayrettin, Haas Jürgen, Wildemann Brigitte
Journal of autoimmunity2024DOI: 10.1016/j.jaut.2024.103234
hypocretin-1orexin-A

Quality Score

6/10

Citations

0

Subjects

Human

Peptide Contacts Analysis

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of hypocretin-1, orexin-A in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on hypocretin-1, orexin-A. Not the final word, but a meaningful data point that adds to the weight of evidence.

Key Findings

The review discusses the single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy, highlighting the association between narcolepsy and HLA-DQB1*06:02 allele as well as decreased hypocretin-1 levels in NT1 patients.

Limitations

The study is a review rather than an original research paper, which limits its ability to provide new empirical data. The focus on recent-onset narcolepsy may not be generalizable to all narcolepsy cases.

How to Interpret This Research

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analysis

Highlighting the role of hypocretin-1 in narcolepsy pathogenesis and its potential as a target for peptide-based therapies.

hypocretin-1orexin-A

Hypocretin-1: A Key Player in Narcolepsy Pathogenesis

Published: May 16, 2026 | Source: Journal of autoimmunity (2024) | Category: hypocretin-1, orexin-A

Overview

A recent review published in the Journal of Autoimmunity highlights the critical role of hypocretin-1 (also known as orexin-A) in narcolepsy pathogenesis. This finding underscores the potential for peptide-based therapies targeting this neurotransmitter to alleviate symptoms and possibly treat the condition.

Study Background

Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and, in some cases, sudden muscle weakness triggered by strong emotions (cataplexy). The exact cause of narcolepsy remains unclear, but it has been linked to genetic factors such as the presence of HLA-DQB1*06:02 allele. Additionally, patients with type 1 narcolepsy (NT1) exhibit significantly lower levels of hypocretin-1 in their cerebrospinal fluid (CSF). This review aims to provide a deeper understanding of the cellular mechanisms involved by analyzing single-cell transcriptomics data from recent-onset narcolepsy cases.

What the Research Found

The study reveals that patients with recent-onset narcolepsy, particularly those with NT1, show markedly reduced levels of hypocretin-1 in their CSF. This neurotransmitter is crucial for regulating wakefulness and sleep cycles. The review also emphasizes the strong association between narcolepsy and the HLA-DQB1*06:02 allele, which may contribute to an autoimmune response targeting hypocretin-producing neurons.

What This Means for Peptide Users

The findings suggest that restoring or enhancing hypocretin-1 levels could be a promising therapeutic approach. While current treatments focus on managing symptoms like sleepiness and cataplexy, peptide-based therapies might offer more targeted interventions by addressing the underlying pathophysiology of narcolepsy.

Limitations and Caveats

As this is a review rather than an original research paper, it does not provide new empirical data but synthesizes existing knowledge. Additionally, the focus on recent-onset cases may limit generalizability to all narcolepsy patients, including those with long-term conditions or type 2 narcolepsy (NT2) without cataplexy.

How This Compares to Previous Research

Previous studies have already established a link between hypocretin-1 deficiency and narcolepsy. However, this review adds depth by examining single-cell transcriptomics data, offering insights into the cellular changes that occur in early-stage narcolepsy. The emphasis on HLA-DQB1*06:02 further supports the autoimmune hypothesis of narcolepsy.

Our Analysis

PeptideVault's analysis indicates that while this review consolidates existing knowledge and provides valuable context for future research, it does not introduce novel empirical data. The potential for peptide-based therapies remains promising but requires further investigation through clinical trials to validate efficacy and safety profiles in diverse patient populations.

Key Takeaways

  • Critical Role of Hypocretin-1: The neurotransmitter is essential for regulating wakefulness and sleep cycles.
  • HLA-DQB1*06:02 Association: This genetic marker strongly correlates with narcolepsy, suggesting an autoimmune component.
  • Therapeutic Potential: Peptide-based therapies targeting hypocretin-1 could offer a novel approach to treating narcolepsy.

Original Source

Citation: Huth Alina, Ayoub Ikram, Barateau Lucie et al. (2024). Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.. Journal of autoimmunity. DOI: 10.1016/j.jaut.2024.103234

Access: https://pubmed.ncbi.nlm.nih.gov/38663202/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the Peptide Contacts research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on hypocretin-1, explore our research guides.

Citation

Huth Alina, Ayoub Ikram, Barateau Lucie et al.. (2024). Single cell transcriptomics of cerebrospinal fluid cells from patients with recent-onset narcolepsy.. Journal of autoimmunity. https://doi.org/10.1016/j.jaut.2024.103234

View full text on PubMed

Related Papers

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias Christopher L et al.· Sports medicine (Auckland, N.Z.)· 2026Review

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

Yuan Claire et al.· International journal of molecular sciences· 2026Review

Carbonless amino acids and a carbonless GHK peptide.

Skurski Piotr et al.· Physical chemistry chemical physics : PCCP· 2026Review

The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.

Wen Huijun et al.· Biogerontology· 2026Review

Glycyl-L-histidyl-L-lysine-Cu2

Hu Jing et al.· European journal of pharmacology· 2026Review

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield Cory K et al.· The American journal of sports medicine· 2026Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.